evocatal GmbH Closes New Financing Round
evocatal GmbH has closed € 2 million in growth financing. Thus the industrial biotech company puts itself in a position to continue successfully started projects rigorously to market readiness.
The current financing round is chaired by new investor Roland Oetker, who, together with existing investors High-Tech Gründerfonds (HTGF), Sirius Seedfonds Düsseldorf (SSFD) and business angel Prof. Riesner, provides € 2 million in growth capital. Founded in 2006, evocatal GmbH has laid the groundwork for an ambitious growth strategy with its seed financing in 2007, and with the now completed follow-on financing the company puts itself in a position to continue successfully started projects rigorously to market readiness.
“In addition to our unique technological position, an excellent team of investors is another strength of evocatal. I am very proud that all existing investors collectively participate in the follow-on financing and thus support the adopted growth strategy“, said a delighted Dr. Thorsten Eggert, founder and CEO of evocatal. “This B round enables us not only to realise the development of new products, but also to create an attractive financial structure for future investors.“, explains Eggert.
“Since its foundation, evocatal has held a strong position in the industrial biotechnology market. We are delighted that the funding will support the team of evocatal in its effort to strengthen this position further and, beyond that, facilitate an expansion into existing and attractive new markets “, comments Ron Winkler (SSFD) on the development at evocatal.
Prof. Dr. Karl-Erich Jaeger, Chairman of the Advisory Board, sees with the entry of the new investor primarily the already existing network of experienced investors and top scientists decisively strengthened. “I am very pleased that with Roland Oetker we have not only gained a renowned new investor, but we are also able to strengthen the advisory board of evocatal with a person who has long-standing experience in the successful financing of biotechnology companies “, states Prof. Jaeger.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Eppendorf opens new site in Singapore - Targeted strengthening of customer focus with high-tech laboratory for pipette calibration and extensive range of high-quality laboratory services
Evotec enters partnership with Vienna start-up - Quantro exploits innovative functional-genetic and transcriptomic technologies to address “undruggable” targets
BluCon Biotech and LG Chem enter into unique investment agreement - BluCon Biotech's technology has the potential to be a disruptive game changer in the world's plastics market
Antibiotic ribosomal compounds deciphered - Combating multidrug-resistant bacteria through high-resolution structural imaging
Illumina and Oxford Nanopore Enter into Broad Commercialization Agreement - Single-Molecule DNA Sequencing System Promises Dramatic Improvement in Cost, Speed, Versatility, and Simplicity of Sequencing
CT Atlantic AG Announces Appointment of Michael Höcker to CEO - Cara Lerner joins CT Atlantic as COO
